Osteoprotegerin (OPG) plays a central role in controlling bone resorption. Exogenous administration of OPG has been shown to be effective in preventing osteolysis and limiting the growth of osteolytic metastasis. The objective of this study was to investigate the effects of OPG on osteoblastic prostate cancer (CaP) metastases in an animal model. LuCaP 23.1 cells were injected intra-tibially and Fc-OPG (6.0 mg/kg) was administered subcutaneously three times a week starting either 24 hours prior to cell injection (prevention regimen) or at 4 weeks post-injection (treatment regimen). Changes in bone mineral density at the tumor site were determined by dual x-ray absorptiometry. Tumor growth was monitored by evaluating serum prostate specific antigen (PSA). Fc-OPG did not inhibit establishment of osteoblastic bone lesions of LuCaP 23.1, but it decreased growth of the tumor cells, as determined by decreases in serum PSA levels of 73.0 ± 44.3% (P < 0.001) and 78.3 ± 25.3% (P < 0.001) under the treatment and prevention regimens, respectively, compared to the untreated tumor-bearing animals. Administration of Fc-OPG decreased the proliferative index by 35.0% (P ¼ 0.1838) in the treatment group, and 75.2% (P ¼ 0.0358) in the prevention group. The results of this study suggest a potential role for OPG in the treatment of established osteoblastic CaP bone metastases.
Introduction
A characteristic property of metastatic prostate cancer (CaP) is its propensity to colonize and thrive in skeletal tissue. CaP skeletal metastases are associated with advanced disease and represent a significant therapeutic challenge. Skeletal deposits of metastatic CaP alter the normal physiology of the bone, leading to disruption of the bone remodeling cycles. Normal remodeling is marked by the coordinated activities of bone formation and resorption, which are essential for the proper function and integrity of skeletal tissue [1] . CaP disruption of bone remodeling usually causes a net increase in bone formation leading to the development of osteoblastic lesions [2, 3] ; however, a significant resorptive component is also observed [4] [5] [6] [7] . Release of growth factors from the mineralized matrix during resorption may facilitate the initial seeding and growth of tumor cells in the bone [8] . Many of the proteins involved in these processes have now been identified, and the alterations in bone remodeling observed in CaP bone metastases offer an increasingly attractive target for therapeutic intervention.
A key molecular system that influences bone remodeling consists of receptor activator of NF-jB ligand (RANKL), receptor activator of NF-jB (RANK), and osteoprotegerin (OPG). OPG is a member of the tumor necrosis factor receptor superfamily that functions as a decoy receptor for RANKL. Association of RANKL with OPG prevents it from interacting with its cognate receptor, RANK. An increase in the ratio of OPG to RANKL inhibits the recruitment, activation and survival of osteoclasts and results in increased bone mass. Transgenic mice overexpressing OPG exhibit an osteopetrotic phenotype [9] , while OPG-knockout mice have severe osteoporosis [10, 11] . Thus the OPG/ RANKL ratio is an important element in the control of normal bone remodeling.
The RANKL/RANK/OPG system is also involved in various pathologies associated with metastatic disease in bone [12] . An elevated RANKL/OPG ratio is observed in osteolytic malignancies such as breast cancer and multiple myeloma [13] [14] [15] [16] [17] and we have recently reported increased expression of RANKL in CaP bone metastases [18] . Treatment with Fc-OPG in certain mouse models diminishes growth and osteolytic lesions of myeloma and breast cancer cells in bone [17, 19] . In prostate cancer, Fc-OPG administration decreased the establishment and subsequent intra-osseous growth of C4-2B CaP cells, which stimulate osteoclast formation in vitro [20] , and LNCaP cells, which give rise to mixed osteoblastic/osteolytic lesions [21] . These results suggest that osteoclast activation may play an important role in promoting the initial growth of CaP in the bone environment.
In this study we have used the CaP xenograft LuCaP 23.1, which induces production of new bone, resulting in sclerotic lesions in murine models. Administration of Fc-OPG inhibited the growth of LuCaP 23.1 xenograft in the bone, but did not alter the establishment of skeletal lesions. The results suggest potential benefits of OPG in the treatment of patients with established osteoblastic CaP bone metastases.
Methods

Animal studies
All animal experiments were performed in compliance with the University of Washington Institutional Animal Care and Use Committee and NIH guidelines. The LuCaP 23.1 xenograft was established in our laboratory from a pelvic lymph node metastasis [22, 23] . It elicits a robust osteoblastic reaction in bone [24] . Single-cell suspensions of LuCaP 23.1 cells were used for direct intra-tibial injections as we have previously described [24] .
Thirty-six-week-old Fox Chase SCID male mice (Charles River, Wilmington, Massachusetts) were injected with 1)2 · 10 5 cells into the right tibiae. The animals were then randomized into three groups: 1) a control group (n ¼ 10); 2) a treatment group (n ¼ 10), with Fc-OPG injections beginning 4 weeks after xenograft injections; and 3) a prevention group (n ¼ 10), with Fc-OPG injections beginning 24 h prior to injection of tumor cells. The Fc-OPG used in this study contains the ligand-binding domain of human OPG fused to the Fc domain of human IgG [9, 19] . Fc-OPG (6.0 mg/kg) was administered subcutaneously three times a week; the control group received injections of vehicle (PBS). Tumor burden was monitored during the study by measuring serum levels of prostate specific antigen (PSA). Determination of serum PSA was performed weekly starting at day 16 (IMx Total PSA Immunoassay, Abbot Laboratories, Abbott Park, Illinois). Mice were sacrificed 8 weeks after the xenograft injection. The time of sacrifice was assigned based on serum PSA levels of the control group and the radiographical appearance of the tumored tibiae (indicating mid-stage LuCaP 23.1 osseous tumors). Prior to sacrifice, all mice were radiographed with a diagnostic mammography unit (LoRad, Danbury, Connecticut) with the following settings: 35 kv, 2.3 sec, 20.7 mA/sec. Both tumor-bearing and contralateral tibiae were harvested for bone mineral density (BMD) determinations. Tumor-bearing tibiae were then processed for immunohistochemical analysis.
Bone densitometry
BMD was measured using dual-energy X-ray absorptiometry (DEXA) on an Eclipse peripheral DEXA Scanner (Norland, Ft. Atkinson, Wisconsin). Data analysis was performed with software provided by the company. The region of interest (2.5 mm · 2.5 mm) encompassed the tumor injection site and was located 2.0 mm from the proximal end of the tibiae. Excised tibiae were placed laterally on the scanner for analysis. Scanning was done at 2 mm/s with a resolution of 0.1 mm · 0.1 mm. Short-term BMD precision (% coefficient of variation) was less than 3% for this technique.
Immunohistochemistry
Tibiae with LuCaP 23.1 tumors were processed for histology and immunohistochemistry by fixation in 10% neutral buffered formalin for 24 hours. After fixation, tibiae were decalcified in 10% EDTA for two consecutive 48-hour periods and embedded in paraffin. 5.0-lm longitudinal sections were used for staining. Histological verification of intra-tibial tumors was assessed by hematoxylin and eosin (H&E) staining. Tibial sections were also examined immunohistochemically for expression of PSA and human Ki-67. Briefly, sections were deparaffinized, rehydrated, and incubated for 10 min at room temperature in 3% H 2 O 2 in methanol to block endogenous peroxidase activity. Specimens were blocked for one hour in a cocktail of 5% horse, 5% goat, and 5% chicken serum in 1Â PBS. The sections for Ki-67 staining underwent antigen retrieval in 1Â citrate buffer (pH 6.0) for 10 min. Detection of PSA was performed using a rabbit polyclonal anti-PSA antibody (DAKO, Carpinteria, California), diluted in blocking cocktail, at a concentration of 3 lg/ml for one hour at room temperature. A rabbit polyclonal anit-Ki-67 (DAKO) was used at a dilution of 1:50. Normal rabbit IgG (DAKO) served as the negative control. After incubation of primary antibodies and subsequent washing, sections were stained with biotinylated goat anti-rabbit IgG (DAKO) at a dilution of 1:150 in blocking cocktail for one hour at room temperature. Immunoreactiviy was detected with the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, California) and color-developed with 3,3 0 -diaminobenzidine tetrahydrochloride (DABC). The proliferative index was determined by counting Ki-67-positive nuclei. In every sample, three representative 40x-fields were scored for positive tumor nuclei (85 nuclei on average; control group and prevention group n ¼ 3 animals, treatment group n ¼ 2 animals).
Statistical analysis
Statistical analysis was performed using GraphPad Prism (GraphPad Software, Inc., San Diego, California). Significance of the differences between the groups was determined using a two-tailed Student's t-test. Association between PSA levels and proliferative index was evaluated using the Pearson correlation.
Results
LuCaP 23.1 xenograft grew in the tibiae of SCID male mice and yielded an osteoblastic reaction. Skeletal LuCaP 23.1 lesions were established in 100% of the animals in the control and prevention groups and 90% in the treatment group. Three mice from the control group, two from the treatment group, and one mouse from the prevention group were excluded from analysis due to compromised integrity of the tibial shaft resulting from tumor delivery, and subsequent growth of tumor in muscle. One mouse in the prevention group expired during the study and was excluded from subsequent analysis. Evidence of increased bone mass is observed in the x-rays of the tumor-bearing tibiae ( Figure 1A) . A large volume of new trabecular bone mass was observed in tumor-bearing tibiae of all three groups, but it was most noticeable in the prevention and treatment groups (Figure 1 ). Tumor foci were present in the tibia in all three groups; however, in the groups that received Fc-OPG, tumor foci decreased in size (Figure 1 ).
Bone mineral density
Representative examples of DEXA scans and the effects of Fc-OPG administration on the BMD of LuCaP 23.1-containing and contralateral non-tumorbearing tibiae are shown in Figure 2 . In accordance with its osteoblastic character, LuCaP 23.1 caused significant increases in BMD over the contralateral nontumor-bearing tibiae (P ¼ 0.0004) of the control group. Fc-OPG administration in the treatment group tumor-bearing tibiae did not significantly alter BMD vs LuCaP 23.1-bearing tibiae of the control group (P ¼ 0.2767), but longer administration (8 weeks) of Fc-OPG in the prevention group increased BMD Results were normalized to non-tumor-bearing tibiae of untreated animals, and are presented as mean ± SEM. Significant increases of BMD were observed in the control group tumor-bearing tibiae vs contralateral non-tumored tibiae (P¼ 0.0004). Administration of Fc-OPG caused additional increases in BMD of LuCaP 23.1 tibiae (treatment: P < 0.0001, prevention: P < 0.0001) when compared to non-tumor bearing contralateral tibia. Fc-OPG administration under both regimens also caused increases in BMD in nontumor bearing tibiae vs. control non-tumored tibiae (treatment: P¼0.0081, prevention: P¼0.0026). LuCaP 23.1 causes an osteoblastic reaction in the bone; therefore one may expect that a smaller tumor burden should result in decreased BMD. However, since OPG is a negative regulator of bone lysis, administration of Fc-OPG also causes increases in BMD. (There are two opposing effects of Fc-OPG on BMD: inhibition of tumor growth, which tends to reduce BMD, and inhibition of osteolysis, which increases BMD.) Since we have shown that Fc-OPG inhibits proliferation of LuCaP 23.1 in bone, we attributed the increases in BMD to inhibition of osteolysis by Fc-OPG. The significance of the differences was determined by the Student's t-test. significantly (P ¼ 0.0393) over the BMD of the LuCaP 23.1 tibiae of the control group. Fc-OPG administration under both regimens significantly increased BMD in non-tumor-bearing tibiae (P ¼ 0.0081, P ¼ 0.0026; prevention and treatment, respectively). LuCaP 23.1 causes an osteoblastic reaction in the bone; therefore a smaller tumor burden should lead to lower osteoblast activity and decreased BMD. However, since OPG is a negative regulator of bone lysis, administration of Fc-OPG also causes an increase in BMD. There are two opposing effects of Fc-OPG on BMD -inhibition of tumor growth, which tends to reduce BMD, and inhibition of osteolysis, which increases BMD. Since we have shown that Fc-OPG inhibits proliferation of LuCaP 23.1 in bone, we attribute an observed increase in BMD in the prevention group vs the control to the second effect of Fc-OPG, inhibition of osteolysis.
Serum PSA levels
To monitor tumor burden in the tibiae, serum PSA levels were measured in animals bearing LuCaP 23.1. There was a trend toward reduced serum PSA levels in the prevention and treatment groups, compared to the control group, over the course of the study ( Figure 3A) . At day 56 post-injection, there were significant decreases in PSA levels in both treatment (73.0 ± 44.3%, P < 0.001) and prevention (78.3 ± 25.3%, P < 0.001) groups vs control group. Serum PSA levels are used to detect CaP and monitor the response of the disease to the treatment. However, in some cases serum PSA levels in patients are not always representative of the tumor burden, since various factors present in bone (e.g., IL-6) can affect PSA expression. We have previously shown that the tumor volume of LuCaP 23.1 is correlated with serum PSA levels in animals bearing LuCaP 23.1 subcutaneous tumors as well as tumors in tibiae [22] [23] [24] [25] . Therefore in the present study we conclude that significantly lower levels of PSA in serum of treated animals suggest decreased tumor burden of osteoblastic LuCaP 23.1 in bone.
Proliferation index
Reduced serum PSA levels in animals treated with Fc-OPG suggest a relative reduction in tumor burden [24, 25] . We measured the proliferation index of the LuCaP 23.1 xenografts in tibiae to determine whether reduced PSA levels were associated with a decrease in proliferation of tumor cells in tibiae. Fc-OPG administration under both regimens decreased the proliferative index of LuCaP 23.1 in tibiae (Figure 3b) . The proliferation index of LuCaP 23.1 decreased by 35.0% (P ¼ 0.1838) in the treatment group and 75.2% (P ¼ 0.0358) in the prevention group. A significant correlation was observed between the proliferative index and serum PSA level (Pearson r ¼ 0.771, P ¼ 0.0254).
Discussion
The majority of CaP bone metastases exhibit osteoblastic characteristics, and animal models that possess this trait are therefore of special interest for the study of human disease. However, despite the overall osteoblastic appearance of many CaP bone metastases, an osteolytic component is frequently evident within these lesions. It has been hypothesized that the increased rates of bone-formation and -resorption cycles associated with CaP metastases may promote skeletal metastases [11, 26] . These observations and ideas give rise to the paradox that osteoblastic CaP metastases may be successfully treated by inhibition of osteolysis. In the present study we have sought to investigate this hypothesis by administering the antiresorptive molecule OPG to the LuCaP 23.1 osteoblastic xenograft injected into the tibiae of SCID mice.
Administration of Fc-OPG attenuated LuCaP 23.1 skeletal tumor growth, as indicated by reduced serum PSA levels and a decreased LuCaP 23.1 proliferation index. These observations suggest that normal and/or pathological bone resorption may promote the growth of LuCaP 23.1 cells in bone, and that inhibition of osteolysis blocks or attenuates the growth process. We have reported previously [25] that LuCaP 23.1 in the bone environment causes a decrease in the number of osteoclasts vs normal tibia. We have also shown separately that administration of the osteolysis-inhibiting compounds zoledronic acid [25] and Fc-OPG (our unpublished data) causes a trend toward further decreases in osteoclast numbers in the LuCaP 23.1 model of bone metastasis; however, because LuCaP 23.1 itself inhibits osteoclast formation, the cell numbers involved are very small even without the treatment, and these further decreases generally do not achieve statistical significance.
Inhibition of bone resorption by OPG may also lead to a reduction in available growth-promoting substances liberated from the bone matrix by osteoclast. It is possible that reduction in bone lysis with Fc-OPG treatment reduced the growth of tumor cells by mechanisms related to inhibition of osteolysis. However, another therapeutic mechanism of action might involve direct effects of Fc-OPG on tumor cells. Work from other laboratories [11, 19] indicates that Fc-OPG fails to inhibit the growth of various tumor cells in vitro. This is not surprising, as there are no known signaling receptors for OPG. Nevertheless, OPG may affect tumor cells by blocking RANKL-mediated signals. Cells of the osteoclast lineage, along with breast epithelium and dendritic cells, respond to RANKL signaling, leading to differentiation and survival [27] , and inhibition of this signaling pathway may slow the growth of CaP cells directly. Experimental confirmation of this hypothesis is not possible with the LuCaP 23.1 xenograft because it does not grow in vitro.
In contrast to the observed inhibition of growth of LuCaP 23.1 bone metastases, the rate of establishment of LuCaP 23.1 in the bone was not altered by administration of Fc-OPG. Similarly, we have reported previously that zoledronic acid, another anti-resorptive compound, did not affect the establishment of LuCaP 23.1 growth in the tibia [25] . Lee et al. also failed to observe inhibitory effects of zoledronic acid on tumor establishment of the osteoblastic CaP xenograft LAPC9 in bone [28] . These results contrast with those of an earlier study in which Fc-OPG inhibited the establishment of C4-2B in the tibiae of SCID mice. The particular properties of the tumor models used in the studies may affect the results. In the present study we have used the LuCaP 23.1 xenograft, which yields osteoblastic lesions [24] . Zhang et al. used C4-2B cells [20] , and Yonou et al. used LNCaP [21] , both of which result in mixed lytic/blastic lesions. As with C4-2B, Fc-OPG administration has been shown to inhibit establishment of lytic bone metastases of myleoma and breast [17, 19] . Therefore stimulation of osteolysis by tumor cells appears to be a critical factor in the colonization of bone by tumors that exhibit mixed or osteolytic phenotypes.
Previous animal studies have shown that treatment with Fc-OPG results in a generalized increase in overall bone density [9] . Administration of Fc-OPG for four weeks did not significantly change the BMD of the tumor-bearing tibiae under the treatment regimen vs the untreated LuCaP 23.1 tibiae, although it did significantly increase the BMD in the treated non-tumor-bearing tibiae vs the control nontumor-bearing tibiae. The observed decrease in serum PSA levels and proliferative rate indicates a lower tumor burden in the treatment group. One would therefore expect lower levels of BMD vs the control untreated tumor-bearing tibiae. We hypothesize that the administration of Fc-OPG, in conjunction with an initial LuCaP 23.1 growth period, increased the BMD of the tumored tibiae vs non-tumor-bearing tibiae of the control group.
In conclusion, our results show that administration of Fc-OPG attenuated the growth of the LuCaP 23.1 tumor in the bone environment as determined by serum PSA levels and decreased proliferative index, but it did not inhibit the initial establishment of LuCaP 23.1 osteoblastic bone metastases. While results of this study do not delineate the mechanisms of growth inhibition of osseous CaP metastasis by OPG, they indicate the potential value of employing exogenous Fc-OPG in combination with other therapeutics in the treatment of established CaP-osseous metastasis.
